Question: what is the date mentioned in this letter?

Answer: 1/8/93


Question: what is the contact person name mentioned in letter?

Answer: P. Carter

Question: what is the contact person name mentioned in letter?

Answer: p. carter


Question: Which corporation's letterhead is this?

Answer: Brown & Williamson Tobacco Corporation


Question: Who is in  cc in this letter?

Answer: T.F. Riehl


Question: what is the subject of  this letter?

Answer: Review of existing Brainstorming Ideas/483


Question: What is the number at the bottom of the page, in bold?

Answer: 499150498


Question: What is written below the logo which looks like three leaves?

Answer: B&W


Question: How many points are there in modifications to readout instrumentation

Answer: 5

Question: How many points are there in modifications to readout instrumentation

Answer: 5.


Question: what is the date in the letter

Answer: June 11, 1990

Question: what is the date in the letter

Answer: June 11,1990


Question: To whom this is addressed

Answer: Dr.K.S.Houghton


Question: Who sent the letter?

Answer: Ted Sanders


Question: Which part of Virginia is this letter sent from

Answer: Richmond


Question: What sort of communication/letter is this ?

Answer: INTER-OFFICE CORRESPONDENCE


Question: What is the date mentioned in the letter?

Answer: April 27, 1990


Question: Which test is used to evaluate ART menthol levels that has been shipped?

Answer: A second Danchi Test


Question: What is the subject of the document/letter?

Answer: Flavor Development Monthly Summary for April, 1990


Question: what is the index for Retention of Franchise

Answer: 100

Question: what is the index for Retention of Franchise

Answer: (100)


Question: What is the source

Answer: USMM 1/95-6/95, 12-Month Data


Question: The number mentioned on the right of the leftside margin?

Answer: 314002838


Question: Heading of the document

Answer: Domestic Product Development

Question: Heading of the document

Answer: Domestic Product Development (cont'd.)

Question: Heading of the document

Answer: DOMESTIC PRODUCT DEVELOPMENT (cont'd.)


Question: what mm Marlboro Menthol were subjectively smoked by the Richmond Panel

Answer: 80mm and 83mm


Question: Cigarettes will be produced and submitted to O/C Panel for what purpose?

Answer: evaluation of lip release


Question: Another model of the 83mm with zero ventilation will be made at Semiworks within how many weeks

Answer: 2-3 weeks

Question: Another model of the 83mm with zero ventilation will be made at Semiworks within how many weeks

Answer: next 2-3 weeks

Question: Another model of the 83mm with zero ventilation will be made at Semiworks within how many weeks

Answer: within the next 2-3 weeks


Question: Under BOLD, primary production of Blend #24- will be completed by which date

Answer: 6/7/90


Question: During the process of prototype production and ringtipping, some cigarettes were observed to have burn holed in which paper

Answer: Cigarette paper

Question: During the process of prototype production and ringtipping, some cigarettes were observed to have burn holed in which paper

Answer: cigarette paper


Question: Heading of the document?

Answer: Memorandum

Question: Heading of the document?

Answer: MEMORANDUM


Question: Where was the conference held?

Answer: B&W Headquarters

Question: Where was the conference held?

Answer: B&W headquarters


Question: How many distinct mechanisms appear to play a role in the breakup of a smoke column into a multi-dimensional flowfield?

Answer: Two

Question: How many distinct mechanisms appear to play a role in the breakup of a smoke column into a multi-dimensional flowfield?

Answer: At least two


Question: One variable that has implicitly not been controlled?

Answer: influence of the test chamber (glass mouth) geometry.

Question: One variable that has implicitly not been controlled?

Answer: The influence of the test chamber (glass mouth) geometry


Question: What is the full form of PUF?

Answer: polyurethane foam

Question: What is the full form of PUF?

Answer: POLYURETHANE FOAM


Question: Which hetero-atoms  does polar compounds contain?

Answer: NITROGEN, SULFUR AND OXYGEN

Question: Which hetero-atoms  does polar compounds contain?

Answer: nitrogen, sulfur and oxygen.


Question: What is the full form of POVC?

Answer: POLAR VOLATILE ORGANICS


Question: Who presented the results on cabin air quality study in commercial aircraft?

Answer: D. J. Eatough

Question: Who presented the results on cabin air quality study in commercial aircraft?

Answer: D. J. EATOUGH

Question: Who presented the results on cabin air quality study in commercial aircraft?

Answer: D. J. EATOUGH (BRIGHAM YOUNG UNIVERSITY)


Question: What is the slope mentioned in the first table?

Answer: 0.1088102E+01


Question: What is the date mentioned in the second table?

Answer: 05-12-92


Question: What is the S.D. mentioned in the DOSE-ug 0.0000 in the third table?

Answer: 10.6


Question: Where were the two magnesium containing  papers made at?

Answer: University of Maine


Question: Which base paper will be coated in-house with various levels of mono potassium phosphate and malonic acid in order to optimize the system?

Answer: 091

Question: Which base paper will be coated in-house with various levels of mono potassium phosphate and malonic acid in order to optimize the system?

Answer: The 091 Base paper


Question: Hand sheets were made utilizing a 30% level of which component?

Answer: a high surface area magnesium carbonate semihydrate

Question: Hand sheets were made utilizing a 30% level of which component?

Answer: high surface area magnesium carbonate semihydrate made by the pyrolysis of magnesium ammonium carbonate

Question: Hand sheets were made utilizing a 30% level of which component?

Answer: a high surface area magnesium carbonate semihydrate made by the pyrolysis of magesium ammonium carbonate


Question: which cigarette would be better if offered on a thicker cigarette

Answer: low smoke

Question: which cigarette would be better if offered on a thicker cigarette

Answer: low smoke cigarette

Question: which cigarette would be better if offered on a thicker cigarette

Answer: These smokers said that a low smoke cigarette would be better if offered on a thicker cigarette


Question: How much percent had not noticed any difference in the odor of VSSS

Answer: Over Fifty percent

Question: How much percent had not noticed any difference in the odor of VSSS

Answer: over fifty percent


Question: who were bothered by cigarette odors

Answer: Nonsmokers

Question: who were bothered by cigarette odors

Answer: nonsmokers

Question: who were bothered by cigarette odors

Answer: Nonsmokers were bothered by cigarette odors


Question: What is the heading of first table?

Answer: Slim Cigarettes

Question: What is the heading of first table?

Answer: SLIM CIGARETTES


Question: What is RIP-6 value for KOOL KS?

Answer: 6I/6


Question: What is the heading of second table

Answer: K. C. Cigarettes


Question: What is the cigarette code of RIP-6(W/O Filter) 21/4SE

Answer: P4049-99(5C)


Question: What is the name of the corporation?

Answer: brown & Williamson tobacco corporation

Question: What is the name of the corporation?

Answer: BROWN & WILLIAMSON TOBACCO corporation


Question: What is the subject?

Answer: Reduced Ignition Propensity/498

Question: What is the subject?

Answer: reduced ignition propensity/498


Question: What is the meeting date?

Answer: January 24, 1994

Question: What is the meeting date?

Answer: January 24 , 1994


Question: How many one-on-one  interviews were completed during April 10th through the April 12th?

Answer: forty


Question: According to the listed requirements , what must be the age group of female smokers?

Answer: between the ages of 18 and 55


Question: According to the requirements what is the minimum required consumption of a regular brand?

Answer: 1/2 pack


Question: How many focus groups were held?

Answer: Two


Question: Which interviews covered the same topics, except packaging, that were discussed in groups?

Answer: The one-on-one

Question: Which interviews covered the same topics, except packaging, that were discussed in groups?

Answer: one-on-one interviews

Question: Which interviews covered the same topics, except packaging, that were discussed in groups?

Answer: The one-on-one interviews


Question: What is the Best Prototype mentioned?

Answer: 327391


Question: What is the BLEND mentioned?

Answer: bw-6071

Question: What is the BLEND mentioned?

Answer: BW-6071


Question: What is the LBS AT TARGET of TOTAL STRIPS?

Answer: 10,000.0 @ 15.0 %


Question: What is the SOLID LBS of T2F GRADE?

Answer: 510

Question: What is the SOLID LBS of T2F GRADE?

Answer: 510.0


Question: What is the title of the letter?

Answer: interoffice memorandum

Question: What is the title of the letter?

Answer: INTEROFFICE MEMORANDUM


Question: To whom is this letter addressed?

Answer: mr. roger jennings


Question: What is the subject of the letter?

Answer: Effect of Chemical Stimulation on the Perception of Draw

Question: What is the subject of the letter?

Answer: effect of chemical stimulation on the perception of draw


Question: What is the PROPOSAL NO.?

Answer: R9044

Question: What is the PROPOSAL NO.?

Answer: r9044


Question: When did the Human Research Committee meet to consider the proposal?

Answer: November 27, 1990


Question: For what does the Bristol tippings have high ink weights for?

Answer: Cork-on-white tipping

Question: For what does the Bristol tippings have high ink weights for?

Answer: cork-on-white tipping


Question: When the cigarette was smoked into the filter, what had 5% flare-up while the low silicate ink tipping had 1% flare-up?

Answer: standard ink tipping

Question: When the cigarette was smoked into the filter, what had 5% flare-up while the low silicate ink tipping had 1% flare-up?

Answer: the standard Ink tipping


Question: Which inks give significantly lower filter flare-up rates?

Answer: low silicate inks


Question: What is the 10 digits number written bold on the paper?

Answer: 2022155810


Question: What is the name of the tobacco company?

Answer: R J Reynolds

Question: What is the name of the tobacco company?

Answer: RJ Reynolds

Question: What is the name of the tobacco company?

Answer: RJ REYNOLDS

Question: What is the name of the tobacco company?

Answer: R J Reynolds tobacco company

Question: What is the name of the tobacco company?

Answer: RJREYNOLDS tobacco company


Question: who is this Interoffice Memorandum addressed to?

Answer: J. D. Phillips


Question: What is the date mentioned?

Answer: June 18, 1992


Question: What is the title of the second paragraph?

Answer: even puff-by-puff filter development (eppcat)

Question: What is the title of the second paragraph?

Answer: Even Puff-by-Puff Filter Development (EPPCAT)?


Question: What is the name of the company?

Answer: B&W


Question: What is the share of the 21-25 segment mentioned?

Answer: 0%


Question: What is the index value for Retention of Franchise ?

Answer: 100

Question: What is the index value for Retention of Franchise ?

Answer: (100)


Question: What is the date mentioned?

Answer: December 20, 1993

Question: What is the date mentioned?

Answer: DECEMBER 20, 1993


Question: What is the subject of the email?

Answer: TAR/NICOTINE DELIVERIES


Question: What is the name of the person in the "FROM" field?

Answer: J. T. WINEBRENNER


Question: What is the Ecusta of Cig. Code 498062 mentioned in RIP-6?

Answer: 6I/6


Question: What is the 9 digits number mentioned in bold?

Answer: 584100575


Question: Cig. Code 498062 and B&W 6SE  is mentioned in which RIP?

Answer: RIP-4


Question: What is the title of the document?

Answer: KOOL ULTRA KS / 100


Question: Which is more superior out of Ultra KS Prototype  or Salem Ultra 100 among rep mentol ultra smokers?

Answer: Ultra KS Prototype


Question: KOOL "C" With Conventional Filter Will Be Adopted Based On The Acceptability Of The?

Answer: KOOL LTS KS CPT Results

Question: KOOL "C" With Conventional Filter Will Be Adopted Based On The Acceptability Of The?

Answer: The Kool LTS KS CPT results


Question: What is the 9 digits number mentioned on the left margin?

Answer: 399000387


Question: What is the first line of the address mentioned at the top?

Answer: Reynolds Building


Question: What is the date mentioned?

Answer: May 4, 2000


Question: To whom is this letter addressed?

Answer: W.E.Claflin


Question: What is the date mentioned?

Answer: June 19, 1990


Question: What is the subject of the document?

Answer: Modifications to Eight-Port Sidestream Instrument


Question: What is the date mentioned in the document ?

Answer: June 19, 1990


Question: Heading of the document?

Answer: Kool Improvement

Question: Heading of the document?

Answer: KOOL IMPROVEMENT


Question: How many samples were produced?

Answer: 300

Question: How many samples were produced?

Answer: Over 300


Question: What is the third point mentioned in Project Basis Technologies?

Answer: Increased Humectants


Question: What is the 9 digits number mentioned on the left border at the bottom?

Answer: 399000380


Question: What is the Objective of the document?

Answer: Develop a Kool KS Product that is superior to Newport among Kool KS Smokers

Question: What is the Objective of the document?

Answer: Develop A KOOL KS Product That Is Superior To Newport Among KOOL KS Smokers


Question: When was the KOOL "C" With 0.51% Menthol Implemented?

Answer: 1993

Question: When was the KOOL "C" With 0.51% Menthol Implemented?

Answer: in 1993


Question: Heading of the document?

Answer: Kool KS

Question: Heading of the document?

Answer: KOOL KS


Question: What is the 9 digits number mentioned on the left margin?

Answer: 399000381


Question: What is the STRAIN TA100,REV/CIG of G7-25 with 1.0% turkish extract?

Answer: 12621


Question: What is the sample of the STRAIN TA100, REV/MG TAR 1094?

Answer: Low extract G7 with 0.5% turkish extract


Question: What is the date mentioned?

Answer: May 29, 1990


Question: To whom is this letter addressed?

Answer: R.Ferguson


Question: What is the subject of the document?

Answer: EPA/AWMA International Symposium, 1990


Question: What is the 10 digits number mentioned in bold on the right margin, at the bottom?

Answer: 2022155944


Question: How many months have the data given here been extracted?

Answer: 12

Question: How many months have the data given here been extracted?

Answer: 12-month

Question: How many months have the data given here been extracted?

Answer: 12 months

Question: How many months have the data given here been extracted?

Answer: 12-Month Data


Question: What is the Retention of Franchise?

Answer: 79.2%

Question: What is the Retention of Franchise?

Answer: 79.2%    (98)


Question: What is the Index of Single Brand Users in the Franchise?

Answer: 119

Question: What is the Index of Single Brand Users in the Franchise?

Answer: (119)


Question: What is the share of the 21-25 segment mentioned?

Answer: 0.5%

Question: What is the share of the 21-25 segment mentioned?

Answer: 0.5%     (50)


Question: What is the status of the KOOL MILDS KS?

Answer: KOOL "C" With 0.63% Menthol Was Implemented In April 1995

Question: What is the status of the KOOL MILDS KS?

Answer: Kool "C" with 0.63% menthol was implemented in April 1995


Question: What is the objective of the KOOL MILDS KS?

Answer: Using Kool "C" Technologies, Develop a Kool Milds KS Product which Tests at Parity or Better to Current Kool Milds KS among Kool Milds KS Smokers

Question: What is the objective of the KOOL MILDS KS?

Answer: Using KOOL "C" Technologies, Develop A KOOL Milds KS product Which Tests At Parity Or Better To Current KOOL Milds KS AMong KOOL Milds KS Smokers


Question: What is the name of the company?

Answer: B&W

Question: What is the name of the company?

Answer: Kool Milds KS


Question: When was the KOOL "C" With 0.63% Menthol Implemented?

Answer: April 1995


Question: Whose assistance will be provided in the manufacture of these tobacco products?

Answer: R&D

Question: Whose assistance will be provided in the manufacture of these tobacco products?

Answer: R&D Assistance

Question: Whose assistance will be provided in the manufacture of these tobacco products?

Answer: R&D assistance


Question: Where is the tobacco being shipped to?

Answer: B & W Tobacco Corporation

Question: Where is the tobacco being shipped to?

Answer: B&W Tobacco Corporation, Development Center, Dock 10F, Lee & McCloskey Streets, Louisville , Kentucky


Question: Where can be the labels used to identify these tobaccos obtained?

Answer: Wayne Sanders, Macon Q.A.


Question: what is the CGR for the age group 21-25?

Answer: -0.68%


Question: which age group is having the highest estimated growth rate or CGR?

Answer: 51+


Question: which age group is having the lowest estimated growth rate or CGR?

Answer: 26-35


Question: Between which years estimated growth rates have been taken?                          ?\

Answer: 1995-2000


Question: which brands did camel exotic blends compliment?

Answer: Turkish and domestic blend .

Question: which brands did camel exotic blends compliment?

Answer: the brand's Turkish and Domestic blend with rare tobaccos and flavorful spices


Question: what does camel crema deliver?

Answer: a creamy indulgent flavor that offers an intriguing and pleasurable smoking experience.


Question: How are speciality blends packed?

Answer: stylish tins with graphics

Question: How are speciality blends packed?

Answer: In stylish tins with graphics


Question: What is the date mentioned?

Answer: September 20, 1985


Question: To whom is this letter addressed?

Answer: Ms. Goldstein

Question: To whom is this letter addressed?

Answer: Ms. Linda Goldstein


Question: The amounts of which elements depend on the local water supply?

Answer: Sodium, Potassium and Calcium

Question: The amounts of which elements depend on the local water supply?

Answer: sodium, potassium and calcium


Question: Where does the complete listing of ingredients in Pepsi products appear?

Answer: on each package.


Question: What is the word written in bold black in the first picture?

Answer: Coke

Question: What is the word written in bold black in the first picture?

Answer: Coke ®


Question: What is the name of the beverages company?

Answer: Shasta

Question: What is the name of the beverages company?

Answer: Shasta Beverages

Question: What is the name of the beverages company?

Answer: Shasta beverages

Question: What is the name of the beverages company?

Answer: Shasta BEVERAGES


Question: Which is the new second generation high fructose syrup?

Answer: F R U C T O S E  5 5

Question: Which is the new second generation high fructose syrup?

Answer: FRUCTOSE 55


Question: What is the date mentioned?

Answer: July, 1979

Question: What is the date mentioned?

Answer: JULY, 1979


Question: What is the DEXTROSE (GLUCOSE) level?

Answer: 42

Question: What is the DEXTROSE (GLUCOSE) level?

Answer: 42%


Question: What is the date mentioned in the header of the document?

Answer: 10/19/2016


Question: Coca-Cola targeted how many Connecticut legislative proposals for taxes on beverages?

Answer: two


Question: What is the Commission File No.?

Answer: 001-02217

Question: What is the Commission File No.?

Answer: Commission File No. 001-02217


Question: What is the name of the place the UNITED STATES SECURITIES AND EXCHANGE COMMISSION is from?

Answer: Washington

Question: What is the name of the place the UNITED STATES SECURITIES AND EXCHANGE COMMISSION is from?

Answer: Washington, d.c.

Question: What is the name of the place the UNITED STATES SECURITIES AND EXCHANGE COMMISSION is from?

Answer: Washington, D.C.

Question: What is the name of the place the UNITED STATES SECURITIES AND EXCHANGE COMMISSION is from?

Answer: Washington, D.C. 20549


Question: What is the COMMON STOCK PAR VALUE?

Answer: $0.25


Question: Where is One Coca-Cola Plaza located?

Answer: Atlanta, Georgia

Question: Where is One Coca-Cola Plaza located?

Answer: Atlanta, georgia


Question: In which year manufacture of carbonated water began ?

Answer: 1772


Question: In how many countries coca-cola markets its products?

Answer: more than 155 countries


Question: What does the carbon dioxide  produce in soft drinks ?

Answer: produces the distinctive "sparkling" quality and that "bubbling" effect as the drink is poured from the container.


Question: Who reviewed about the safety of carbon dioxide in food?

Answer: by a group of prominent scientists for the food and drug administration


Question: Which company's consumer information center is given here?

Answer: Coca-Cola USA


Question: what is the average intake of sodium in US ?

Answer: 3000-5000 milligrams per day

Question: what is the average intake of sodium in US ?

Answer: 3,000-5,000 milligrams per day

Question: what is the average intake of sodium in US ?

Answer: estimated to be3000-5000 milligrams per day

Question: what is the average intake of sodium in US ?

Answer: the average intake of sodium in the U.S. is estimated to be 3,000-5,000 milligrams per day


Question: What is the  average U.S per capita consumption of soft drinks based on national sales estimates?

Answer: is approximately two and one-half six-ounce servings.


Question: What is the estimated average intake of sodium per day in the U.S.?

Answer: is estimated to be 3,000-5,000 milligrams per day.


Question: what the contact number of  consumer information centre?

Answer: 1-800-438-2653

Question: what the contact number of  consumer information centre?

Answer: (1-800-438-2653)


Question: what is the gross profit in the year 2009?

Answer: 19,902

Question: what is the gross profit in the year 2009?

Answer: 19,902 millions


Question: what is the income before income tax for  the year 2007?

Answer: 7919

Question: what is the income before income tax for  the year 2007?

Answer: 7,919

Question: what is the income before income tax for  the year 2007?

Answer: 7,919 millions


Question: what is the basic net income per share for 2009 vs 2008

Answer: 18%


Question: what is the consolidated net income in the year 2008

Answer: 5,874

Question: what is the consolidated net income in the year 2008

Answer: 5,784 millions


Question: what is the operating margin in the year 2009

Answer: 26.6%


Question: To whom, the letter is addressed?

Answer: Mr . Thomas:

Question: To whom, the letter is addressed?

Answer: Mr. W. Thomas


Question: Who is the consumer correspondence of coca cola USA?

Answer: kimberly boyer


Question: What is the date mentioned in the letter?

Answer: March 4, 1991


Question: whats the name of company ?

Answer: Shasta Beverages Inc.

Question: whats the name of company ?

Answer: Shasta Beverages INC.


Question: Who is this letter sent to ?

Answer: Ms. Liebman

Question: Who is this letter sent to ?

Answer: Ms.Liebman

Question: Who is this letter sent to ?

Answer: Ms. Bonnie Liebman


Question: who is the vice president of shasta beverages?

Answer: Cecil B. Lowry


Question: What is the date mentioned in this letter?

Answer: January 14, 1980


Question: Who has written the comments?

Answer: Michael F. Brown and Richard L. Frank

Question: Who has written the comments?

Answer: Michael f. brown and richard l. frank


Question: what is the name of the food institute

Answer: the American Frozen food institute

Question: what is the name of the food institute

Answer: the american frozen food institute


Question: What is the date mentioned in the document?

Answer: July 17 , 1978


Question: what does the phosphoric acid contain ?

Answer: mineral phosphorous


Question: how many milligrams americans consume phosphorus per day

Answer: 1200-1600 milligrams


Question: What happens when a tooth is placed in an acid solution & is left there for a number of days?

Answer: erosion will take place.


Question: On which date this statement was passed?

Answer: June 9, 1978


Question: who is the vice president of the quaker oats company?

Answer: robert o. nesheim

Question: who is the vice president of the quaker oats company?

Answer: ROBERT O. NESHEIM

Question: who is the vice president of the quaker oats company?

Answer: robert o. nesheim, Ph.d.


Question: What was the subcommitteeon?

Answer: health and scientific research

Question: What was the subcommitteeon?

Answer: HEALTH AND SCIENTIFIC RESEARCH


Question: What is the date mentioned in the document?

Answer: JUNE 9, 1978


Question: which country is benefited from the successful integration of jugos de valle?

Answer: Latin America


Question: What is the increase in net operating revenues as part of favorable impact of currency fluctuations?

Answer: by approximately 2 percent.


Question: Which financial year's net operating revenues are compared?

Answer: Year ended December 31, 2009, versus Year Ended December 31, 2008


Question: In which country is the consumer information centre located?

Answer: Georgia

Question: In which country is the consumer information centre located?

Answer: Atlanta, Georgia 30301


Question: Which acid do the coca-cola company use to provide a pleasant tartness?

Answer: phosphoric acid


Question: what does soft drinks provide ?

Answer: refreshing and positive contribution to everyday living

Question: what does soft drinks provide ?

Answer: a refreshing and positive contribution to everyday living


Question: what has been playing a significant role in soft drink industry?

Answer: High Fructose corn sweeteners

Question: what has been playing a significant role in soft drink industry?

Answer: high fructose corn sweeteners


Question: what is the percentage reduction in calories in the fructose sweetened soft drinks?

Answer: 10-12%


Question: What is the average calories decreased over the past decade in the United States?

Answer: 11%


Question: In which year diet coke was introduced in United States?

Answer: 1982


Question: what is the percentage decline in the number of calories Americans consumed from caloric sweeteners between 2000 and 2010?

Answer: more than 11%

Question: what is the percentage decline in the number of calories Americans consumed from caloric sweeteners between 2000 and 2010?

Answer: more than 11%.


Question: what is the name of the food institute?

Answer: AFFI

Question: what is the name of the food institute?

Answer: American Frozen food Institute

Question: what is the name of the food institute?

Answer: THE AMERICAN FROZEN FOOD INSTITUTE


Question: How many members are included in the frozen food institute?

Answer: more than 400

Question: How many members are included in the frozen food institute?

Answer: more than 400 members


Question: AFFI stands for ?

Answer: American Frozen Food Institute

Question: AFFI stands for ?

Answer: American frozen food institute


Question: This statement or comments is submitted on behalf of?

Answer: AFFI

Question: This statement or comments is submitted on behalf of?

Answer: The American Frozen food institute

Question: This statement or comments is submitted on behalf of?

Answer: The American Frozen food institute ("AFFI")


Question: where does the high fructose corn will come from ?

Answer: major corn refiners in the midwest

Question: where does the high fructose corn will come from ?

Answer: major corn refiners in the midwest.

Question: where does the high fructose corn will come from ?

Answer: from major corn refiners in the Midwest


Question: for foreseeable future what will be our only nutritive sweetener?

Answer: Fructose

Question: for foreseeable future what will be our only nutritive sweetener?

Answer: fructose


Question: What stops companies like coke and pepsi from using fructose widely?

Answer: Franchise bottler system

Question: What stops companies like coke and pepsi from using fructose widely?

Answer: franchise bottler system


Question: this letter was written to whom?

Answer: Michael Jacobson

Question: this letter was written to whom?

Answer: Michael jacobson


Question: On  which date was  this letter was written

Answer: 17 March 1975

Question: On  which date was  this letter was written

Answer: 17 march 1975


Question: who is the editor who signed this letter?

Answer: Bill Wolf


Question: under which corporation this letter has been written

Answer: united consumer service corporation

Question: under which corporation this letter has been written

Answer: The United Consumer Service Corporation


Question: For what price is the film kit plus teacher's guide available?

Answer: is available for $3.50.


Question: The story is designed to interest whom?

Answer: middle elementary school level children and older


Question: Heading of the document?

Answer: The start of a fine home library


Question: What is the price of the token?

Answer: $1

Question: What is the price of the token?

Answer: $1 each


Question: How many pages does the volume contain?

Answer: 1300

Question: How many pages does the volume contain?

Answer: 1300-page


Question: How many stories are present in The works of Kipling?

Answer: 139 stories


Question: Heading of the document?

Answer: Thirst is a pretty good reason for drinking

Question: Heading of the document?

Answer: THIRST IS A PRETTY GOOD REASON FOR DRINKING


Question: What is the name of the company?

Answer: The Coca-Cola Company

Question: What is the name of the company?

Answer: The Coca-Cola company


Question: What are critical for well-being of people today?

Answer: Nutritious food, balanced diets


Question: Where was the meeting held?

Answer: Atlanta


Question: When will the announcement be held?

Answer: Tuesday


Question: Who is the chairman of Coca-Cola company?

Answer: Roberto Goizueta

Question: Who is the chairman of Coca-Cola company?

Answer: Roberto C. Goizueta


Question: What is the DOCKET NO?

Answer: 8839


Question: When was this document issued?

Answer: October 5, 1973


Question: Who is the secretary?

Answer: Charles A. Tobin


Question: who is the chairman of the council on children, media and merchandising?

Answer: Robert Choate


Question: What is the name of the office mentioned in the letter?

Answer: Freedom of information office


Question: who has signed the letter?

Answer: Bonnie Liebman


Question: what is the heading of the document?

Answer: Nutrition Action

Question: what is the heading of the document?

Answer: Nutrition action


Question: By whom  a great deal of advertising is produced locally?

Answer: bottlers

Question: By whom  a great deal of advertising is produced locally?

Answer: bottlers,


Question: who began voluntarily listing Yello #5 on its labels well before the FDA required

Answer: Pepsi-Cola Company

Question: who began voluntarily listing Yello #5 on its labels well before the FDA required

Answer: pepsi-cola company


Question: artificial colour only fulfils whose labelling requirements

Answer: federal labeling requirements


Question: what was removed from the diets of hyperactive children as part of the study?

Answer: food coloring


Question: what sort of certification is this

Answer: Certification of Translation


Question: What is the specialization  of international litigation services?

Answer: international cases and foreign language document processing


Question: when is this executed on

Answer: 27th day of August 2013


Question: who is the managing director of international litigation services

Answer: Joseph Thorpe


Question: who conducted pivotal studies

Answer: Takeda


Question: What findings are not duplicated in mouse, monkey, or dog?

Answer: Rat

Question: What findings are not duplicated in mouse, monkey, or dog?

Answer: Rat Findings


Question: quantity of the product code 15102

Answer: 1


Question: what are the greatest sources of caffeine?

Answer: coffee, tea and chocolate

Question: what are the greatest sources of caffeine?

Answer: coffee, tea and chocolate.


Question: In which year did American Council on Science and Health , published "the health effects of caffeine"?

Answer: 1983


Question: What add little to the average total intake of caffeine?

Answer: soft drinks


Question: what produces a number of caffeine free soft drink for those who prefer no caffeine in their diets?

Answer: Pepsi-Cola

Question: what produces a number of caffeine free soft drink for those who prefer no caffeine in their diets?

Answer: pepsi-cola


Question: Where is the Coca-cola company foods division located?

Answer: Houston, Texas


Question: From which department the letter is issued?

Answer: Department of health, education, and welfare


Question: whose signature at the bottom of page ?

Answer: Alexander Grant

Question: whose signature at the bottom of page ?

Answer: alexander grant


Question: what is the date mentioned at the top of the page?

Answer: November 14, 1986


Question: who is the consumer correspondent?

Answer: Anita Pancotto

Question: who is the consumer correspondent?

Answer: anita pancotto


Question: Who is this letter sent to?

Answer: Mr. Alm

Question: Who is this letter sent to?

Answer: Mr. John R. Alm


Question: what is the designation of Mr.john r alm?

Answer: President and Chief Operating Officer

Question: what is the designation of Mr.john r alm?

Answer: president and chief operating officer


Question: what is the president's healthierUS goal ?

Answer: helping americans live longer, better and healthier lives.


Question: what is the reason to applaud Alm?

Answer: personal commitment to helping the children of los angeles build bright futures through camp paintrock


Question: what is the title of the page?

Answer: Sing With Me

Question: what is the title of the page?

Answer: sing with me


Question: what happens if i sip on my coke while i sing my song according to letter?

Answer: it cools my throat


Question: where is the place of coca-cola companyas  mentioned in the letterhead?

Answer: Atlanta, Georgia

Question: where is the place of coca-cola companyas  mentioned in the letterhead?

Answer: atlanta,georgia


Question: Who is this letter addressed to?

Answer: Ms. Lerza

Question: Who is this letter addressed to?

Answer: Ms. Catherine Lerza


Question: what was the company's first protein containing beverage?

Answer: Saci

Question: what was the company's first protein containing beverage?

Answer: saci


Question: What is the letter dated?

Answer: November 1, 1972

Question: What is the letter dated?

Answer: November 1 ,  1972


Question: What is the designation of the sender in this letter?

Answer: Public Relations Assistant

Question: What is the designation of the sender in this letter?

Answer: public relations assistant


Question: what is the page number mentioned in this letter?

Answer: -3-


Question: who is the senior vice president ?

Answer: Alan L. Hoffman


Question: what is the date mentioned in the letter?

Answer: April 15,2014

Question: what is the date mentioned in the letter?

Answer: April 15, 2014


Question: who is the executive director?

Answer: Mr. Michael jacobson

Question: who is the executive director?

Answer: mr. Michael jacobson


Question: where is Alan L.hoffan working ?

Answer: global public policy and government affairs


Question: In how many countries global company is operating ?

Answer: more than 220


Question: What kind of study is mentioned in this letter?

Answer: Study on soft drinks

Question: What kind of study is mentioned in this letter?

Answer: the study on soft drinks.


Question: What is the date mentioned on the top of the letter ?

Answer: July 29, 1972


Question: What is the date of this letter?

Answer: July 29, 1972

Question: What is the date of this letter?

Answer: July 29,  1972


Question: who is the president and chief operating officer?

Answer: John R Alm

Question: who is the president and chief operating officer?

Answer: John R. Alm


Question: what is the 2nd point inthe letter ?

Answer: Reaffirm our decades-old strict policy and guidelines regarding the marketing and advertising of our brands to children.


Question: What sort of document series does it covers ?

Answer: Ingredient Series

Question: What sort of document series does it covers ?

Answer: Soft Drink Ingredient Series


Question: What is the title of the series?

Answer: SOFT DRINKS AND CAFFEINE


Question: What is the title of the document?

Answer: SOFT DRINKS AND CAFFEINE


Question: What is the fullform of ils?

Answer: international litigation services

Question: What is the fullform of ils?

Answer: INTERNATIONAL LITIGATION SERVICES


Question: What type of certification is mentioned in this document?

Answer: CERTIFICATION OF TRANSLATION


Question: Who is the Managing Director of International Litigation Services, Inc?

Answer: Joseph Thorpe

Question: Who is the Managing Director of International Litigation Services, Inc?

Answer: joseph thorpe


Question: what is the heading of the document of the document

Answer: Memorandum of Meeting

Question: what is the heading of the document of the document

Answer: memorandum of meeting


Question: What place is mentioned  in document

Answer: commissioner's FB#8 conference Room

Question: What place is mentioned  in document

Answer: commissioner's fb#8 conference room


Question: What is the subject of document?

Answer: Labeling

Question: What is the subject of document?

Answer: labeling


Question: Who seems to be following America's footsteps?

Answer: Japan


Question: What is the Telephone Number given?

Answer: 301/436-2373


Question: What is the fulll form of FDA?

Answer: Food & Drug Administration

Question: What is the fulll form of FDA?

Answer: FOOD & DRUG ADMINISTRATION


Question: What is the full form of CFSAN?

Answer: Center for Food Safety and Applied Nutrition


Question: Which department is mentioned in the letter head?

Answer: DEPARTMENT OF HEALTH & HUMAN SERVICES


Question: Who is the President of Corn Refiners Association?

Answer: Audrae Erickson


Question: When was this letter received?

Answer: 07-03-2008


Question: What is the date mentioned in the letter?

Answer: July 28, 1972


Question: who is marketing director?

Answer: Robert L. Goldsmith

Question: who is marketing director?

Answer: Robert l. goldsmith


Question: who published the national magazine for all boys ?

Answer: the boy scouts of america


Question: What are the scheduled public gatherings on?

Answer: food labeling

Question: What are the scheduled public gatherings on?

Answer: on food labeling


Question: How much percent of consumers reads labels?

Answer: 20

Question: How much percent of consumers reads labels?

Answer: 20%

Question: How much percent of consumers reads labels?

Answer: 20 percent


Question: What is the heading of the document?

Answer: Memorandum of Meeting

Question: What is the heading of the document?

Answer: memorandum of meeting


Question: what is the main ingredient of soft drink?

Answer: Carbonated Water

Question: what is the main ingredient of soft drink?

Answer: Carbonated water


Question: What is the heading in right corner ?

Answer: What's in Soft Drinks

Question: What is the heading in right corner ?

Answer: WHAT'S IN SOFT DRINKS


Question: What is are the words written in bold in second paragraph?

Answer: Caffeine and Other Alleged Health Related Effects


Question: What is the second reference mentioned?

Answer: PepsiCo, Inc., The Physical or Technical Effect of Caffeine in Cola Beverages, Purchase, N.Y., July 20, 1981


Question: Which university does the sixth reference mention?

Answer: University of Florida


Question: Which year is mentioned in the first reference?

Answer: 1983


Question: What is the docket No?

Answer: 78N-0158


Question: What is the date in document?

Answer: September 27, 1978


Question: What is the date mentioned on the document?

Answer: January 29, 2016


Question: With whom is the meeting being conducted?

Answer: Sandy Douglas

Question: With whom is the meeting being conducted?

Answer: Sandy Douglas, Coca-Cola Co.


Question: What is the date mentioned in the header of the document?

Answer: January 29, 2016


Question: what is the title of the page?

Answer: historical background


Question: what are the common sources of caffeine consumed by humans?

Answer: coffee beans, tea leaves, kola nuts and cocoa beans


Question: what is widely distributed naturally occuring substance found in more than 60 plant species throughout he world?

Answer: caffeine


Question: who is traditionally  attributed to legendary for the first written mention of a coffee containing beverage tea?

Answer: Shen nung

Question: who is traditionally  attributed to legendary for the first written mention of a coffee containing beverage tea?

Answer: Chinese emperor Shen nung

Question: who is traditionally  attributed to legendary for the first written mention of a coffee containing beverage tea?

Answer: chinese emperor shen nung


Question: who were treated to a sweetened chocolate drink by aztec emporer montezuma?

Answer: spanish conquerors

Question: who were treated to a sweetened chocolate drink by aztec emporer montezuma?

Answer: the Spanish conquerors


Question: What is the name of the person mentioned to Contact?

Answer: Carlton

Question: What is the name of the person mentioned to Contact?

Answer: Carlton Curtis


Question: Which year is COCA-COLA beginning with a new taste?

Answer: 100

Question: Which year is COCA-COLA beginning with a new taste?

Answer: 100th year

Question: Which year is COCA-COLA beginning with a new taste?

Answer: its 100th year


Question: What is the date mentioned?

Answer: April 23, 1985


Question: Who said, "The best has been made even better"?

Answer: Mr. Goizueta

Question: Who said, "The best has been made even better"?

Answer: Roberto C. Goizueta

Question: Who said, "The best has been made even better"?

Answer: Roberto C. Goizueta, chairman of the Board and Chief executive officer of The Coca-Cola Company


Question: H ow many years of advertising is mentioned?

Answer: 95

Question: H ow many years of advertising is mentioned?

Answer: 95 years


Question: What is the date mentioned?

Answer: Feb 4, 1982

Question: What is the date mentioned?

Answer: Feb. 4, 1982


Question: Whose name is mentioned to  Contact?

Answer: Tony Tortorici

Question: Whose name is mentioned to  Contact?

Answer: Tony tortorici


Question: who is the managing director of international litigation services ?

Answer: Joseph Thorpe


Question: When it executed?

Answer: 28th day of August 2013


Question: Where was the translation executed at?

Answer: Aliso Viejo, California

Question: Where was the translation executed at?

Answer: In aliso Viejo, california


Question: What is the heading of the document?

Answer: Response Document


Question: What are mixed with α, γ?

Answer: α, γ


Question: What are the renal effects mentioned?

Answer: urine electrolytes, osmolality, pH

Question: What are the renal effects mentioned?

Answer: (urine electrolytes, osmolality, pH)


Question: From whom has this email been sent?

Answer: Kanayama Kiyoshi


Question: Who are on the CC list?

Answer: Shephard, Kirk (TPI); Fuse, Touichirou (TPC)


Question: What is the email ID of Kanayama Kiyoshi?

Answer: Kanayama_Kiyoshi@takeda.co.jp


Question: What is the subject of this email?

Answer: Re: Potential Publicaton in Correspondence Section of The Lancet


Question: What is the level of importance of the email send by Witte, Kimberly?

Answer: High


Question: What is the subject of the document?

Answer: fw: skb problems

Question: What is the subject of the document?

Answer: FW: SKB PROBLEMS


Question: What is the EXHIBIT number mentioned?

Answer: 9


Question: What is the exhibit no given in the document?

Answer: 9


Question: Who is this Memo to?

Answer: Distribution

Question: Who is this Memo to?

Answer: distribution


Question: What is the date mentioned?

Answer: July 19, 2002

Question: What is the date mentioned?

Answer: JULY 19, 2002


Question: Whose signature is present at the bottom?

Answer: Marlene C. Dubas

Question: Whose signature is present at the bottom?

Answer: MARLENE C. DUBAS


Question: who are in the cc?

Answer: johnston,Kendra; precurato-grubb, marti


Question: what is the "subject" of this letter?

Answer: article in today's USA Today regarding Avandia hearing


Question: who is writing this letter?

Answer: chen, gigi

Question: who is writing this letter?

Answer: CHEN, GIGI

Question: who is writing this letter?

Answer: gigi m. chen, MBA


Question: when was this letter sent?

Answer: 7/31/2007 11:48:09 AM

Question: when was this letter sent?

Answer: 7/31/2007 11:48:09 am


Question: who is the premier sales representative ?

Answer: gigi m.chen

Question: who is the premier sales representative ?

Answer: gigi m. chen, MBA


Question: What is the cellular number of Gigi M. Chen?

Answer: 716.725.7100


Question: Who is the 23rd Addressee mentioned in the list?

Answer: Senior Vice President, Accounting Center


Question: Heading of the document?

Answer: Draft Agenda

Question: Heading of the document?

Answer: Draft Agenda?


Question: What are the timings for Continental Breakfast?

Answer: 8:00-9:00


Question: what is the title of this page?

Answer: Executive Summary, cont.

Question: what is the title of this page?

Answer: executive summary, cont.


Question: what is the first point under the title-executive summary, cont.

Answer: Proposed experiments

Question: what is the first point under the title-executive summary, cont.

Answer: proposed experiments


Question: Heading of the document?

Answer: Response Document

Question: Heading of the document?

Answer: response document


Question: What is the full form of FDA?

Answer: Food and Drug Administration


Question: What is the date mentioned?

Answer: January 3, 2003


Question: Who is the sender of this fax?

Answer: Jena Weber


Question: What is the total no of pages in the fax including cover?

Answer: 1


Question: who is writing this letter?

Answer: Marlene Dubas

Question: who is writing this letter?

Answer: marlene dubas


Question: who is in the cc?

Answer: Tom Muldoon

Question: who is in the cc?

Answer: tom muldoon


Question: Which all  compaies are added as defendants in a lawsuit?

Answer: Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals America, Inc.


Question: what is 'RE' in the letter?

Answer: Preservation of Documents and Electronic Data relating to Actos

Question: what is 'RE' in the letter?

Answer: preservation of documents and electronic data relating to actos


Question: Heading of the first paragraph?

Answer: SIXTH OBJECTION


Question: Name of the judge?

Answer: Patrick Hanna


Question: What is the page no mentioned in this document?

Answer: 3


Question: When was the hearing before Judge?

Answer: July 25, 2013


Question: What is the date mentioned?

Answer: January 14, 1999


Question: What is the company name ?

Answer: ELI LILLY AND COMPANY


Question: Which benefit start after 1 year of service?

Answer: Extended Disability

Question: Which benefit start after 1 year of service?

Answer: extended disability


Question: What is the name of the company mentioned in the letterhead?

Answer: DEPARTMENT OF HEALTH & HUMAN SERVICES


Question: What is the fullform of NDA?

Answer: new drug application

Question: What is the fullform of NDA?

Answer: New drug application.


Question: What is the name of the addressee?

Answer: Ms. Pritza

Question: What is the name of the addressee?

Answer: Mary Jo Pritza, MPH, PharmD


Question: What kind of a letter is  this ?

Answer: DISCIPLINE REVIEW LETTER


Question: When did Regulatory affairs department receive this letter?

Answer: Feb 19 2007

Question: When did Regulatory affairs department receive this letter?

Answer: FEB 19 2007


Question: What is the date mentioned?

Answer: August 16, 1999


Question: To whom is this letter addressed?

Answer: Alan

Question: To whom is this letter addressed?

Answer: Alan D. Mackenzie


Question: What is the full form of TPA?

Answer: Takeda Pharmaceuticals America

Question: What is the full form of TPA?

Answer: Takeda Pharmaceuticals America Inc.

Question: What is the full form of TPA?

Answer: Takeda Pharmaceuticals America, Inc.


Question: Which two companies have agreed to amend the Co-Promotion Agreement?

Answer: Takeda Pharmaceuticals America, Inc. ("TPA") and Eli Lilly and Company ("Lilly")


Question: What is the name of the company?

Answer: THE UPJOHN COMPANY


Question: What is the date mentioned?

Answer: September 21, 1993


Question: To whom is this letter addressed?

Answer: Matsuzawa

Question: To whom is this letter addressed?

Answer: Doctor Matsuzawa

Question: To whom is this letter addressed?

Answer: Tai Matsuzawa, Ph.D

Question: To whom is this letter addressed?

Answer: Tai Matsuzawa, Ph.D.


Question: As a consequence of the decision Upjohn must decline participation with which company?

Answer: Takeda


Question: A 79-year-old female was enrolled in the study for how many days?

Answer: 200 days


Question: The patient had a history of bladder cancer since when?

Answer: 1996

Question: The patient had a history of bladder cancer since when?

Answer: since 1996


Question: Who is the writer of the document?

Answer: Janet L. Haskins


Question: The woman had a positive history of what?

Answer: tobacco use


Question: Who is the general manager of International development Dept. of Takeda Chemical Industires, Ltd.?

Answer: K. Kitazawa, Ph. D.


Question: what is the name of the industry ?

Answer: TAKEDA CHEMICAL INDUSTRIES, LTD.

Question: what is the name of the industry ?

Answer: TAKEDA CHEMICAL INDUSTRIES , LTD .


Question: How many pages are there in total?

Answer: 2

Question: How many pages are there in total?

Answer: Page 2 of 2


Question: what is the month and date mentioned in this letter, at the top ?

Answer: October 25

Question: what is the month and date mentioned in this letter, at the top ?

Answer: october 25


Question: By whom is this document written?

Answer: Stacey Dixon Calahan


Question: What is the date mentioned?

Answer: January 21, 1999


Question: To whom is this document addressed?

Answer: Mr. Ellingson

Question: To whom is this document addressed?

Answer: Mr. Larry Ellingson


Question: By whom is this document written?

Answer: Kunio Iwatani


Question: What is written in big bold letters at the bottom?

Answer: DALY 19


Question: to which department it belongs to ?

Answer: DEPARTMENT OF HEALTH AND HUMAN SERVICES

Question: to which department it belongs to ?

Answer: department of health and human services.


Question: what is the date of submission?

Answer: 11/18/2002


Question: what is the telephone number (include area code)?

Answer: 847-383-3739


Question: What is the serial number mentioned in the form?

Answer: 5 0 1


Question: what is the expiration date ?

Answer: November 30, 2002

Question: what is the expiration date ?

Answer: november 30, 2002


Question: what is  the name of the sponsor ?

Answer: Takeda Pharmaceuticals North America, Inc.

Question: what is  the name of the sponsor ?

Answer: Takeda Pharmaceuticals North america , Inc.


Question: what has to be investigated before starting pioglitazone therapy?

Answer: any macroscopic haematuria


Question: what has been experienced commonly in patients taking actos in combination with insulin?

Answer: Heart failure

Question: what has been experienced commonly in patients taking actos in combination with insulin?

Answer: heart failure


Question: Which medicine is used to treat type 2 diabetes mellitus?

Answer: Actos/Competact


Question: How many cases of bladder cancer from 12506 patients were reported?

Answer: 19 cases


Question: Which foundation is mentioned in this document?

Answer: Cleveland Clinic Foundation

Question: Which foundation is mentioned in this document?

Answer: The Cleveland Clinic Foundation


Question: Under which department , The Cleveland Clinic Foundation operates?

Answer: Department of Cardiovascular Medicine

Question: Under which department , The Cleveland Clinic Foundation operates?

Answer: Department of Cardiovascular Medicine.


Question: What is the PO Box number?

Answer: 931535


Question: What is the Tax ID mentioned in this document?

Answer: 34-0714585


Question: what is the IND mumber (if previously assigned ) ?

Answer: 33,729


Question: What is the serial number mentioned in the form?

Answer: 4 9 7


Question: what is the date of submission ?

Answer: 11/1/02


Question: what is the Name(s) of drug (include all available names: Trade , Generic, Chemical, Code)?

Answer: ACTOS (pioglitazone HCI)

Question: what is the Name(s) of drug (include all available names: Trade , Generic, Chemical, Code)?

Answer: ACTOS  (Pioglitazone HCI)


Question: what is the form approved : OMB No

Answer: 0910-0014

Question: what is the form approved : OMB No

Answer: 0910-0014.


Question: What is the word written in bold on the top of the document?

Answer: Takeda


Question: What is the date mentioned?

Answer: 19th January 2012


Question: To whom was this letter written?

Answer: Healthcare Professional


Question: what is the name of pharmaceuticals ?

Answer: Takeda Pharmaceuticals North America, Inc.

Question: what is the name of pharmaceuticals ?

Answer: TAkeda pharmaceuticals North America ,INc.


Question: to whom this letter is written ?

Answer: Ms. Haskins

Question: to whom this letter is written ?

Answer: Janet L. Haskins

Question: to whom this letter is written ?

Answer: janet L. haskins


Question: When did Regulatory affairs department receive this letter?

Answer: JUN 16 2003


Question: To whom a copy of cover letter has to be sent ?

Answer: Ms. Jens Weber


Question: What is the fifth point?

Answer: WAC and AWP generally;

Question: What is the fifth point?

Answer: WAC AND AWP generally;


Question: Education grants regarding which products?

Answer: TPNA

Question: Education grants regarding which products?

Answer: TPNA products


Question: What is the date this document was last printed?

Answer: 11/30/2012

Question: What is the date this document was last printed?

Answer: 11/30/2012 4:28:00 AM


Question: Which reimbursement for TPNA pharmaceutical products is generally given?

Answer: Medicare and Medicaid


Question: What is the designation of Alfonso T. Perez, M.D.?

Answer: Vice President, Clinical Research


Question: By whom was this agreement Agreed and Accepted?

Answer: Richard A. Rudick

Question: By whom was this agreement Agreed and Accepted?

Answer: Richard A. Rudick, M.D.

Question: By whom was this agreement Agreed and Accepted?

Answer: Richard A. Rudick, M.D. Chairman, Division of Clinical Research


Question: What is the full form of FAR?

Answer: Federal Acquisitions Regulation


Question: What is the date of the signature of the chairman of the Division of clinical research?

Answer: 5/8/07


Question: What is the number written above TAK-INDNDA-01577086?

Answer: 425


Question: What is the contact number of Ms. Jena Weber, Regulatory Project Manager?

Answer: 301-827-6422


Question: What is the full form of ODE?

Answer: Office of Drug Evaluation


Question: What is written above Page 2 on the top?

Answer: IND 33, 729


Question: what is the unit mentioned in the letter ?

Answer: 7200


Question: what is the date mentioned

Answer: 9/23/93


Question: Name of the first person in the To list?

Answer: PJ Daniels

Question: Name of the first person in the To list?

Answer: pj Daniels


Question: from whose desk this letter is  written ?

Answer: timothy J Gumbleton

Question: from whose desk this letter is  written ?

Answer: Timothy J. Gumbleton


Question: Whose letter's copy is attached?

Answer: Dr. Mitchell

Question: Whose letter's copy is attached?

Answer: DR. Mitchell


Question: what is the date mentioned ?

Answer: February 6, 1996

Question: what is the date mentioned ?

Answer: february 6 , 1996


Question: to whom this letter is written  ?

Answer: Dr. K. KItazawa

Question: to whom this letter is written  ?

Answer: Dr . k. Kitazawa


Question: this letter is written by whom ?

Answer: T. Suzuki

Question: this letter is written by whom ?

Answer: Tsuyoshi Suzuki , M S .


Question: Which laboratory is T. Suzuki associated with ?

Answer: Drug Safety Research Laboratories

Question: Which laboratory is T. Suzuki associated with ?

Answer: drug safety research laboratories .


Question: what is the date mentioned in  the letter

Answer: August 8, 2002

Question: what is the date mentioned in  the letter

Answer: august 8 , 2002


Question: What is the name of the industry given here?

Answer: Takeda chemical industries, LTD .

Question: What is the name of the industry given here?

Answer: TAKEDA CHEMICAL INDUSTRIES, LTD.


Question: to whom this letter is written ?

Answer: Dr. Thom

Question: to whom this letter is written ?

Answer: Dr. Claire Thom


Question: what is the name mentioned in CC

Answer: Mr. S. Hamanaka

Question: what is the name mentioned in CC

Answer: Mr . S . Hamanaka


Question: Who sent this letter?

Answer: Katsuhisa Saito

Question: Who sent this letter?

Answer: katsuhisa saito


Question: what is Ref: code  mentioned ?

Answer: TPNA-TS-020808


Question: What is the venue mentioned in the document?

Answer: TPNA, Chicago


Question: What is the date mentioned in the document?

Answer: Monday, 12 and Tuesday, 13 August 2002


Question: what is the fax number  mentioned in the letter at the top?

Answer: 06 6204 2244


Question: Which drug's toxicity study results will be discussed ?

Answer: pioglitazone


Question: what is the date and time mentioned ?

Answer: 10/27/93 09:36:07


Question: what is mentioned in the subject ?

Answer: Pioglitazone statement

Question: what is mentioned in the subject ?

Answer: pioglitazone statement


Question: To whom this email was send?

Answer: PETER J. DANIELS

Question: To whom this email was send?

Answer: PJ DANIEL--PW17PO PETER J. DANIELS


Question: what is the date mentioned in the forwarding note ?

Answer: 10/26/93

Question: what is the date mentioned in the forwarding note ?

Answer: 10/26/93 15:44


Question: what is the time mentioned in the forwarding note ?

Answer: 15:44


Question: To whom this email was forwaded?

Answer: RUPPEL, PATRICIA

Question: To whom this email was forwaded?

Answer: PLRUPPEL--RCC1 RUPPEL, PATRICIA


Question: what is the name of the company

Answer: THE UPJOHN COMPANY


Question: what is the date and year mentioned ?

Answer: September 21, 1993

Question: what is the date and year mentioned ?

Answer: september 21 , 1993


Question: Which company is mentioned in the letterhead?

Answer: THE UPJOHN COMPANY


Question: in which country the upjohn company is located ?

Answer: USA

Question: in which country the upjohn company is located ?

Answer: U.S.A


Question: what is the fax mentioned ?

Answer: 06 6204 2244


Question: what is year date and time mentioned?

Answer: 2002 08/08 21:49


Question: what is the name of the division ?

Answer: Takeda Develop division

Question: what is the name of the division ?

Answer: TAKEDA DEVELOP DIVISION


Question: to whom they can ask directly to disclose the details of "promotion study"?

Answer: FDA


Question: what is the date mentioned in the  letter

Answer: 8 January 2003

Question: what is the date mentioned in the  letter

Answer: 8 january 2003


Question: To whom this letter is addressed?

Answer: MPDRAP I Leader


Question: what is mentioned in the CC?

Answer: CEOs and General Managers of Pharmaceutical Units

Question: what is mentioned in the CC?

Answer: CEOs and general managers of pharmaceutical units


Question: combination therapy in the us market accounts for how much % of total actos sales .

Answer: 64

Question: combination therapy in the us market accounts for how much % of total actos sales .

Answer: 64%


Question: What is the due date to evaluate data from actos 507?

Answer: August 5


Question: who is the lead responsibility for developing additional monitoring plan for actos 508

Answer: Amy Hagaman

Question: who is the lead responsibility for developing additional monitoring plan for actos 508

Answer: Amy hagaman


Question: what is the due date for "draft  justification for actos 508" ?

Answer: August 12

Question: what is the due date for "draft  justification for actos 508" ?

Answer: august 12


Question: when was this  last updated ?

Answer: August 1, 2002

Question: when was this  last updated ?

Answer: august 1, 2002


Question: Who is the lead responsible person for draft justification for actos 508?

Answer: Amy Hagaman/Alfonso Perez


Question: How many pages are there in total as part of this document?

Answer: 7


Question: Which is the core organization of Takeda pharmaceutical Company?

Answer: Pharmaceutical Development Division

Question: Which is the core organization of Takeda pharmaceutical Company?

Answer: Pharmaceutical development Division


Question: Who made the opening remarks ?

Answer: Dr. Kitazawa


Question: When is the clinical expert meeting scheduled?

Answer: October 1 and 2

Question: When is the clinical expert meeting scheduled?

Answer: for October 1 and 2.


Question: Why was it suggested to prepare non-clinical "White paper"?

Answer: to address the bladder issue

Question: Why was it suggested to prepare non-clinical "White paper"?

Answer: to address the bladder issue.


Question: What is Ms Wakamatsu's role in Dept. Strategic Development?

Answer: Assistant Manager

Question: What is Ms Wakamatsu's role in Dept. Strategic Development?

Answer: Assistant manager


Question: what is the date mentioned in the given information ?

Answer: 20 April 2006

Question: what is the date mentioned in the given information ?

Answer: 20 april 2006


Question: What is the meeting time mentioned here?

Answer: 4:00pm - 5:00pm


Question: what is the place mentioned ?

Answer: Meeting Room 403

Question: what is the place mentioned ?

Answer: meeting room 403


Question: who will forward the article regarding rosiglitazone and non clinical bladder data to andy ?

Answer: Mondira


Question: What date is the meeting scheduled to develop the overall structure of the document?

Answer: in early May


Question: Who presented an outline of the Cohen hypothesis?

Answer: Philip Collett


Question: What is significant in the development of calculi?

Answer: Raising the pH of male rat urine above 6.5


Question: What is the correlation observed in cohen's paper?

Answer: 0.61


Question: Why didn't rats eliminate calculi as humans do?

Answer: Because rats are quadropeds

Question: Why didn't rats eliminate calculi as humans do?

Answer: Because rats are quadropeds.


Question: Who challenged authorities regrading implementing monitoring plan?

Answer: Takeda Europe


Question: What content is high in male rat urine?

Answer: protein

Question: What content is high in male rat urine?

Answer: protien content


Question: What is the fullform of MAA?

Answer: Marketing Authorization Application


Question: Which forum is mentioned in this document?

Answer: Takeda Global Risk Management Forum

Question: Which forum is mentioned in this document?

Answer: Takeda Global Risk Management Forum/March 22, 2004


Question: What is the issued date of this document?

Answer: August 13, 2002

Question: What is the issued date of this document?

Answer: august 13, 2002


Question: Who is the Director of Nonclinical Safety and Efficacy?

Answer: David Baron

Question: Who is the Director of Nonclinical Safety and Efficacy?

Answer: David baron


Question: Who described tumor promoter-model study?

Answer: Dr.  El-Hage

Question: Who described tumor promoter-model study?

Answer: dr. el-hage


Question: What is the duration of daily dosing?

Answer: 32-weeks

Question: What is the duration of daily dosing?

Answer: 32-weeks after BBN.


Question: What is the exhibit number?

Answer: 107


Question: Who updated the CEO on August 6?

Answer: Mr. Saito


Question: By when should TPNA send outline of response to TCI ?

Answer: August 19

Question: By when should TPNA send outline of response to TCI ?

Answer: by August 19


Question: When will Mr. Saito present outline to CEO?

Answer: August 20

Question: When will Mr. Saito present outline to CEO?

Answer: on August 20


Question: By when will the document be finalized?

Answer: August 26

Question: By when will the document be finalized?

Answer: by August 26


Question: When will the FDA Conference Call be held?

Answer: July 31, 2002


Question: On the purpose of teleconference, how many topics were to be discussed?

Answer: 3

Question: On the purpose of teleconference, how many topics were to be discussed?

Answer: 3 topics


Question: What is the date mentioned at the bottom?

Answer: 09/18/12


Question: What is the heading of the document?

Answer: ACTOS FDA RESPONSE TASK FORCE-TPNA


Question: How many key issues does the FDA have with respect to the non-clinical data related to bladder tumors?

Answer: 3

Question: How many key issues does the FDA have with respect to the non-clinical data related to bladder tumors?

Answer: The FDA has 3 key issues with respect to the non-clinical data related to bladder tumors.


Question: What plan is developed by TPNA?

Answer: monitoring plan

Question: What plan is developed by TPNA?

Answer: TPNA will develop monitoring plan.


Question: What is TPNA's goal?

Answer: is to supply justification to support maintaining current labeling.


Question: When was this document last updated?

Answer: August 1, 2002


Question: What is the last point in the table?

Answer: Evaluate Impact on Tak-559

Question: What is the last point in the table?

Answer: EVALUATE IMPACT ON TAK-559


Question: What is the Draft's Due Date?

Answer: August 5


Question: What kind of meeting is mentioned in this letter?

Answer: ACTOS FDA RESPONSE MEETING


Question: what kind of drug is used to treat the group of rats?

Answer: Pioglitazone

Question: what kind of drug is used to treat the group of rats?

Answer: pioglitazone


Question: what kind of cell tumours experienced the same frequency when group of rats treated with pioglitazone?

Answer: transitional

Question: what kind of cell tumours experienced the same frequency when group of rats treated with pioglitazone?

Answer: transitional cell tumors


Question: In the rat oncogenicity study, what was observed in male rats?

Answer: thickening of the bladder and hypertrophy of the urothelium


Question: What is the time span where no tumors are seen?

Answer: shorter term (12 month)


Question: According to mouse oncogenicity study, what was seen male mice only?

Answer: hyperplasia


Question: who conducted robust program?

Answer: TCI


Question: What is the due date to conduct review meeting for FDA package?

Answer: August 22


Question: Who is the lead responsible person for the  compilation of FDA package?

Answer: Larry Hancock


Question: What is the task assigned to David Baron?

Answer: Send nonclinical rationale/justification section to medical writing for compilation

Question: What is the task assigned to David Baron?

Answer: Send nonclinical rationale/justification section to medical writing for compilation.


Question: Who is responsible for sending  package to TCI/EU for review?

Answer: Mary Ramstack


Question: What is the due date for sending FDA Document to Regulatory Affairs?

Answer: August 26


Question: What is the last updated date mentioned in this document?

Answer: August 1, 2002

Question: What is the last updated date mentioned in this document?

Answer: August 1,  2002


Question: Which product's liability claims are described here?

Answer: ACTOS PRODUCTS

Question: Which product's liability claims are described here?

Answer: ACTOS PRODUCTS LIABILITY CLAIMS


Question: What is the date mentioned in this document at the bottom?

Answer: 1/11/2007


Question: What is the exhibit number?

Answer: 52


Question: Mention the first name listed in the "apologies"?

Answer: Professor Ele Ferrannini


Question: when was  the last meeting/conference call held on ?

Answer: 15 October 2005

Question: when was  the last meeting/conference call held on ?

Answer: 15th October 2005


Question: what is the date mentioned under the title - " minutes of conference call"?

Answer: 28th November 2005

Question: what is the date mentioned under the title - " minutes of conference call"?

Answer: Monday 28th November 2005

Question: what is the date mentioned under the title - " minutes of conference call"?

Answer: monday 28th november 2005


Question: What is the heading of this document?

Answer: Rationale for 3 Segments

Question: What is the heading of this document?

Answer: Rationale for 3 segments


Question: What is the graphical representation about?

Answer: Summary of Segment Attractiveness


Question: On what basis, the Summary of Segment Attractiveness is carried out?

Answer: current situation & future trends

Question: On what basis, the Summary of Segment Attractiveness is carried out?

Answer: based on current situation & future trends

Question: On what basis, the Summary of Segment Attractiveness is carried out?

Answer: Based on current situation & future trends.


Question: What are the three segments indicated in the graph?

Answer: Treatment Machines, Life Negotiators, Struggle for Control


Question: What is the conclusion obtained from the graph?

Answer: All 3 segments have consistent needs

Question: What is the conclusion obtained from the graph?

Answer: All 3 Segments Have Consistent Needs.


Question: what is the title of chapter 3?

Answer: Document Storage Period

Question: what is the title of chapter 3?

Answer: document storage period


Question: what is the "document storage period " article number?

Answer: 7

Question: what is the "document storage period " article number?

Answer: Article 7


Question: mention the second point listed under the article 7(document storage period)?

Answer: To be stored for ten years

Question: mention the second point listed under the article 7(document storage period)?

Answer: to be stored for ten years


Question: what is article 4?

Answer: principles of creating documents

Question: what is article 4?

Answer: PRINCIPLES OF CREATING DOCUMENTS

Question: what is article 4?

Answer: (PRINCIPLES OF CREATING DOCUMENTS)


Question: what is the title of chapter 2?

Answer: document storage functions

Question: what is the title of chapter 2?

Answer: DOCUMENT STORAGE FUNCTIONS


Question: What does article 5 in this document describes?

Answer: principles concerning document storage functions

Question: What does article 5 in this document describes?

Answer: (principles concerning document storage functions)


Question: what is article 6?

Answer: duties of responsible person in charge of storage and person in charge of storage

Question: what is article 6?

Answer: DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE

Question: what is article 6?

Answer: (DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE)


Question: Semi exclusive rights in how many countries?

Answer: 20

Question: Semi exclusive rights in how many countries?

Answer: 20 countries


Question: What percent is the Supply Price / Royalty Rate?

Answer: 30% supply price

Question: What percent is the Supply Price / Royalty Rate?

Answer: 30% SUPPLY PRICE


Question: In how many countires, license to Exclusive rights are provided?

Answer: 60

Question: In how many countires, license to Exclusive rights are provided?

Answer: 60 COUNTRIES

Question: In how many countires, license to Exclusive rights are provided?

Answer: in approximately 60 countries


Question: what is the name of pediatric program?

Answer: ACTOS

Question: what is the name of pediatric program?

Answer: ACTOS PEDIATRIC PROGRAM


Question: What is the date mentioned in this page?

Answer: 5 October 2006


Question: What is the title of this document?

Answer: Critical Success Factors

Question: What is the title of this document?

Answer: CRITICAL SUCCESS FACTORS


Question: What is the title of this document?

Answer: Consequences of IR


Question: What is the title of this page?

Answer: Actos plan overview

Question: What is the title of this page?

Answer: ACTOS PLAN OVERVIEW


Question: which are prescibed eariler in the treatment of type 2 diabetes under the title of "critical success factors"?

Answer: TZD's

Question: which are prescibed eariler in the treatment of type 2 diabetes under the title of "critical success factors"?

Answer: TZD'S


Question: which has a superior lipid profile(v. avandia and others) under the title of "strength/opportunities?

Answer: ACTOS


Question: What does the graph describes in this document?

Answer: TZD Share of Oral Market

Question: What does the graph describes in this document?

Answer: TZD SHARE OF ORAL MARKET


Question: What is the Plan TZD Share for the year 2003?

Answer: 19.7%


Question: Which year has 13.3% Oral share (TZD)?

Answer: 2000


Question: Which study's synopsis is this?

Answer: clinical

Question: Which study's synopsis is this?

Answer: Clinical Study


Question: what is the code mentioned under the title of clinical study synopsis?

Answer: 01-06-TL-OPI-527


Question: When was expert advisory meeting ?

Answer: 4 october 2006

Question: When was expert advisory meeting ?

Answer: 4 OCTOBER 2006


Question: What is the title of this document?

Answer: Overview of November 2006 Submission

Question: What is the title of this document?

Answer: OVERVIEW OF NOVEMBER 2006 SUBMISSION


Question: What is the full form of PPSR?

Answer: Proposed Pediatric Study Request

Question: What is the full form of PPSR?

Answer: PROPOSED PEDIATRIC STUDY REQUEST


Question: What study is described in the table given?

Answer: PLACEBO- CONTROLLED DOSE RANGING STUDY

Question: What study is described in the table given?

Answer: Glycemic Parameters in a 26-Week Placebo-Controlled Dose-Ranging Study.


Question: Which parameters are considered for the study(see heading of table 2)?

Answer: GLYCEMIC

Question: Which parameters are considered for the study(see heading of table 2)?

Answer: Glycemic Parameters


Question: Prior to what, the patients entered an 8 week washout/run-in-period?

Answer: double-blind treatment


Question: What is the floor supply price?

Answer: $0.17 / 30 mg or Takeda's cost from site of lowest cost


Question: What is the royalty adjustment if generic enters the market ?

Answer: 50%

Question: What is the royalty adjustment if generic enters the market ?

Answer: 50% royalty adjustment


Question: what is the promotional trails data usage  for( Lilly in exclusive) ?

Answer: Split of 70/30

Question: what is the promotional trails data usage  for( Lilly in exclusive) ?

Answer: Split of 70/30 (Lilly in Exclusive)

Question: what is the promotional trails data usage  for( Lilly in exclusive) ?

Answer: split of 70/30 (Lilly in exclusive)


Question: What is the promotional trials data usage for (semi exclusive)?

Answer: 50/50 in Semi-exclusive


Question: What is the title mentioned in this document?

Answer: CSF's and Marketing Objectives

Question: What is the title mentioned in this document?

Answer: CSF'S AND MARKETING OBJECTIVES


Question: what is the name of the plan review ?

Answer: MARKETING PLAN

Question: what is the name of the plan review ?

Answer: MARKETING PLAN REVIEW

Question: what is the name of the plan review ?

Answer: Marketing plan review.


Question: Mention the year given for Actos?

Answer: 2004

Question: Mention the year given for Actos?

Answer: Actos  2004


Question: What is the heading of this document?

Answer: ACTOS FDA Response Strategy

Question: What is the heading of this document?

Answer: ACTOS FDA RESPONSE STRATEGY


Question: What is the last revision date mentioned in this document?

Answer: August 7, 2002


Question: What is the goal of TPNA?

Answer: to supply justification to support maintaining current labeling.


Question: what is the first point given in table for bladder cancer alongside of  clinical findings ?

Answer: observed during preclinical studies in rats

Question: what is the first point given in table for bladder cancer alongside of  clinical findings ?

Answer: OBSERVED DURING PRECLINICAL STUDIES IN RATS


Question: how much percent of  drug quantity present in rezulin under the title of 'clinical findings'?

Answer: 1.7

Question: how much percent of  drug quantity present in rezulin under the title of 'clinical findings'?

Answer: 1.7%


Question: how much percent of placebo present in avandia alongside of the clinical findings?

Answer: 0.20

Question: how much percent of placebo present in avandia alongside of the clinical findings?

Answer: 0.20%


Question: what is the total number of all claims under the title of "summary of litigation risk in the ous territories"?

Answer: 10


Question: what is the total number of drug claims under the title of "summary  of litigation risk in the ous territories"?

Answer: 5


Question: what is the percentage of  TZD share in the year 2000 ?

Answer: 40.3%


Question: what is Actos TRx (000s) in the year 2003 ?

Answer: 9,497


Question: what is the percentage of plan TZD share in the year 2004 ?

Answer: 42.9%


Question: in which month and the year the launch of Merck's PPAR's took place?

Answer: feb 2005

Question: in which month and the year the launch of Merck's PPAR's took place?

Answer: FEB 2005


Question: what is the TZD's TRx (000s) in the year 2005 ?

Answer: 22,902


Question: what is the first TZD used for type 2 patients ?

Answer: Actos

Question: what is the first TZD used for type 2 patients ?

Answer: ACTOS


Question: For which type of diabetes the TZD's prescribed earlier in treatment?

Answer: Type 2 diabetes


Question: what has to be establish as the the best OAD medication by treating insulin resistance ?

Answer: Actos

Question: what has to be establish as the the best OAD medication by treating insulin resistance ?

Answer: ACTOS


Question: What is the Specific example given?

Answer: Pioglitazone: Need to commit to studies to investigate certain signals

Question: What is the Specific example given?

Answer: pioglitazone: need to commit to studies to investigate certain signals


Question: Which country would have similar interest as in Europe?

Answer: usa

Question: Which country would have similar interest as in Europe?

Answer: USA


Question: What is the Suggestion from Glyn?

Answer: TGRD would formulate direct Risk Management plan and obtain Japan's input

Question: What is the Suggestion from Glyn?

Answer: tgrd would formulate direct risk management plan and obtain japan's input


Question: Full form of PEM?

Answer: prescription event monitoring


Question: what is the month and year of overview of submission ?

Answer: November 2006

Question: what is the month and year of overview of submission ?

Answer: NOVEMBER 2006


Question: what is included in the summary document ?

Answer: benefit risk assessment

Question: what is included in the summary document ?

Answer: includes benefit-risk assessment

Question: what is included in the summary document ?

Answer: (includes benefit-risk assessment)


Question: what is the executive summary of bladder cancer cases ?

Answer: CONFIRM


Question: what is the name of the request document ?

Answer: PARTIAL CLINICAL HOLD REMOVAL

Question: what is the name of the request document ?

Answer: Partial clinical hold removal request document

Question: what is the name of the request document ?

Answer: PARTIAL CLINICAL HOLD REMOVAL REQUEST DOCUMENT


Question: who appointed as the responsible person on this issue ?

Answer: Mr. Saito

Question: who appointed as the responsible person on this issue ?

Answer: MR. SAITO


Question: basically by whom the current action plan was approved ?

Answer: CEO


Question: in which month and date it was reported to CEO ?

Answer: August 6

Question: in which month and date it was reported to CEO ?

Answer: AUGUST 6


Question: what has to be reported to CEO on August 20 (japan time) ?

Answer: an outline of the FDA response

Question: what has to be reported to CEO on August 20 (japan time) ?

Answer: AN OUTLINE OF THE FDA RESPONSE


Question: what is the name of the policy on Actos issue ?

Answer: Takeda basic policy

Question: what is the name of the policy on Actos issue ?

Answer: TAKEDA BASIC POLICY


Question: What is the heading of this document, given at the top?

Answer: Avandamet Uptake


Question: What are shown on the x-axis?

Answer: Full Months Post Launch

Question: What are shown on the x-axis?

Answer: FULL MONTHS POST LAUNCH


Question: What is the percentage of Avandamet scripts from Actos mentioned?

Answer: 36

Question: What is the percentage of Avandamet scripts from Actos mentioned?

Answer: 36%


Question: What is on the horizonal axis of the graph?

Answer: Full Months Post Launch


Question: Heading of the document?

Answer: Link between IR and CVD

Question: Heading of the document?

Answer: LINK BETWEEN IR AND CVD


Question: What is the percentage of Nondiabetic patients with prior MI?

Answer: 18.8

Question: What is the percentage of Nondiabetic patients with prior MI?

Answer: 18.8%


Question: who is the chief leader ?

Answer: Mr.K Saito

Question: who is the chief leader ?

Answer: MR. K SAITO


Question: who is the responsible person for TPNA ?

Answer: Dr. C Thom


Question: what is the name of the organization ?

Answer: Actos issue organization

Question: what is the name of the organization ?

Answer: ACTOS ISSUE ORGANIZATION


Question: who is the responsible person of TCI ?

Answer: MR. K SAITO


Question: who is the first contact person of EuR&D ?

Answer: Dr. P Collett

Question: who is the first contact person of EuR&D ?

Answer: DR. P COLLETT


Question: who is the responsible person for EuR&D ?

Answer: Dr. D Eckland

Question: who is the responsible person for EuR&D ?

Answer: DR. D ECKLAND


Question: who is the first contact person of TPNA ?

Answer: Ms. M Ramstack ,Ms. J Haskins

Question: who is the first contact person of TPNA ?

Answer: MS. M RAMSTACK, MS. J HASKINS


Question: who is the first contact person of TCI ?

Answer: Mr. M Miyazaki

Question: who is the first contact person of TCI ?

Answer: MR. M MIYAZAKI


Question: What is the Handwritten sentence on the top?

Answer: Row-Contract (as of 7/19/99)


Question: What is the date mentioned?

Answer: July 19, 1999

Question: What is the date mentioned?

Answer: JULY 19, 1999


Question: With whom is the discussion being held?

Answer: Jim Harper

Question: With whom is the discussion being held?

Answer: JIM HARPER


Question: What is the date of randomisation?

Answer: 05-11-01

Question: What is the date of randomisation?

Answer: 05/11/01


Question: What is the patient number?

Answer: 014


Question: What is the Centre number?

Answer: 49013


Question: What is the Reference mentioned here?

Answer: 135037-hrt-11

Question: What is the Reference mentioned here?

Answer: 135037-HRT-11


Question: What is the heading of the table?

Answer: Weight Changes (kg) from Baseline during Double-Blind Clinical Trials with ACTOS


Question: What is the ACTOS 15 mg of Monotherapy?

Answer: 0.9(-0.5/3.4) N=79

Question: What is the ACTOS 15 mg of Monotherapy?

Answer: 0.9(-0.5/3.4) n=79


Question: What is the trial duration mentioned?

Answer: 16 to 26 weeks

Question: What is the trial duration mentioned?

Answer: 16 TO 26 WEEKS


Question: What is the ACTOS 45 mg of Combination Therapy of Insulin?

Answer: 4.1 (1.4/6.8)  N=338

Question: What is the ACTOS 45 mg of Combination Therapy of Insulin?

Answer: 4.1 (1.4/6.8) N=338


Question: what are secondary endpoints ?

Answer: cardiovascular mortality

Question: what are secondary endpoints ?

Answer: CARDIOVASCULAR MORTALITY


Question: What is  the number of patients ?

Answer: 5,000


Question: What is  "FPV" ?

Answer: June 2001

Question: What is  "FPV" ?

Answer: JUNE 2001


Question: what is the title of this page?

Answer: objectives and methodology

Question: what is the title of this page?

Answer: OBJECTIVES AND METHODOLOGY


Question: what is the name of the form ?

Answer: URGENT DATA ENQUIRY

Question: what is the name of the form ?

Answer: urgent data enquiry form

Question: what is the name of the form ?

Answer: URGENT DATA ENQUIRY FORM


Question: what is the centre number ?

Answer: 49013


Question: what is the date issued mentioned in the form ?

Answer: 22-04-04


Question: what is the patient number ?

Answer: 014


Question: What is the date mentioned?

Answer: August 12-13, 2002


Question: What is the Item that shows Person Responsible Bob Ahlbrandt will send to John?

Answer: Add renal colic to clinical AE search


Question: What is the heading of the document?

Answer: TPNA/TEUR&D/TCI ACTOS RESPONSE MEETING


Question: What is written just below the date?

Answer: Action Item List/Document Timelines


Question: What is the EXHIBIT number mentioned?

Answer: R-12


Question: What is the BOP Number?

Answer: CORP-B-019


Question: What is the Effective Date?

Answer: 05/01/2006


Question: What is the heading of the document?

Answer: TPNA/TEUR&D/TCI ACTOS RESPONSE MEETING


Question: What is the date mentioned?

Answer: August 12-13, 2002


Question: What is the heading of the handwritten words in Pediatric Indication?

Answer: Appendix

Question: What is the heading of the handwritten words in Pediatric Indication?

Answer: appendix


Question: what is the patient number?

Answer: 014


Question: what is diagnosis?

Answer: benign tumor of the urinary bladder


Question: What is the exhibit number?

Answer: 39


Question: Which Procedures No is being decribed here?

Answer: Procedures No. 19


Question: What is Article 4 in this document referred to?

Answer: Disposal Record Ledger


Question: In which Article, Persons In Charge of Retention is described?

Answer: Article 2


Question: how many targeted primary care physicians are included in these meetings ?

Answer: 350


Question: in which month and year eight regional market research consultants meetings were held ?

Answer: October and November 2001

Question: in which month and year eight regional market research consultants meetings were held ?

Answer: october and november 2001


Question: which is an effective and liver-safe agent accepted by the participants ?

Answer: ACTOS


Question: what is an effective and trusted agent ?

Answer: Metformin

Question: what is an effective and trusted agent ?

Answer: metformin


Question: what are the most commonly mentioned reasons not to prescribe TZD's ?

Answer: 1) Cost, 2) Edema/weight gain, and 3) Reimbursement.


Question: what are the challenges of ACTOS positive data?

Answer: small numbers in the studies, non-randomized, company-sponsored.


Question: What does alternate terms include?

Answer: core therapy; cornerstone therapy; first-line.


Question: In U.S. clinical trials, how many patients have received ACTOS?

Answer: OVER 4700

Question: In U.S. clinical trials, how many patients have received ACTOS?

Answer: over 4700 patients


Question: Which medicine is used for treating type 2 diabetes in over 5900 patients?

Answer: ACTOS


Question: in one ACTOS treatment group how much amount of initial dose is given to the patients daily ?

Answer: 7.5 mg

Question: in one ACTOS treatment group how much amount of initial dose is given to the patients daily ?

Answer: 7.5 mg once daily


Question: in a 24 week placebo controlled study how many patients with type 2 diabetes were randomized ?

Answer: 260

Question: in a 24 week placebo controlled study how many patients with type 2 diabetes were randomized ?

Answer: 260 patients


Question: in the second ACTOS treatment group,how much amount of initial dose patients should receive daily ?

Answer: 15 mg

Question: in the second ACTOS treatment group,how much amount of initial dose patients should receive daily ?

Answer: 15 mg once daily


Question: What is the retention time period of monthly reports?

Answer: 30 years


Question: What does Attachment 1 describes?

Answer: List of Retention Periods of Time, Retention Locations


Question: What is the retention time period of contracts?

Answer: Permanently


Question: where participants seemed more cautious more resistant to the entire message?

Answer: In Boston

Question: where participants seemed more cautious more resistant to the entire message?

Answer: in Boston


Question: where were responses more strongly positive than in other cities?

Answer: In Philadelphia

Question: where were responses more strongly positive than in other cities?

Answer: in philadelphia (home of glaxosmithkline)


Question: What is the fullform of ARA?

Answer: Alliance for Risk Assessment


Question: What is the date mentioned in this document?

Answer: March 2017


Question: Who is the President of The Fertilizer Institute?

Answer: Chris Jahn


Question: Roger Johnson is associated with which union?

Answer: National Farmers Union


Question: What is the title of this document?

Answer: CEO Council Members


Question: What is accepted as an effective glucose control agent?

Answer: ACTOS


Question: what are reasons not to prescribe TZDs ?

Answer: 1)cost,2)edema/weight gain, and 3) reimbursement

Question: what are reasons not to prescribe TZDs ?

Answer: 1) Cost, 2) Edema/Weight gain, and 3) Reimbursement.


Question: what is the subheading under the title of "specific findings"?

Answer: Reaction to IR Information

Question: what is the subheading under the title of "specific findings"?

Answer: reaction to IR information

Question: what is the subheading under the title of "specific findings"?

Answer: A. Reaction to IR Information


Question: What is the date mentioned?

Answer: December, 2001


Question: By whom was this document prepared?

Answer: C. Beck

Question: By whom was this document prepared?

Answer: C. Beck, LLC


Question: What is the name of the Article 6?

Answer: Self Inspection


Question: When was this document Enacted?

Answer: 2006 May 31


Question: When was the second revision?

Answer: 2011 April 26


Question: When was this document Revised first?

Answer: 2006 October 20


Question: When was the rule PROPOSED?

Answer: Jan. 19, 2017

Question: When was the rule PROPOSED?

Answer: JAN. 19, 2017


Question: What is the name of the FOUNDATION this PROPOSAL belongs to?

Answer: Toxicology Education Foundation

Question: What is the name of the FOUNDATION this PROPOSAL belongs to?

Answer: TOXICOLOGY EDUCATION FOUNDATION


Question: Who is the vice president of this FOUNDATION?

Answer: William Farland

Question: Who is the vice president of this FOUNDATION?

Answer: William Farland, PhD, ATS


Question: What is the date mentioned at the bottom?

Answer: July 20th 2017


Question: Whose biography is this?

Answer: Christopher Jahn

Question: Whose biography is this?

Answer: CHRISTOPHER JAHN


Question: What is the full form of TFI?

Answer: The Fertilizer Institute


Question: For how many years did Christopher Jahn work for U.S. Senator Craig Thomas?

Answer: 10

Question: For how many years did Christopher Jahn work for U.S. Senator Craig Thomas?

Answer: 10 years

Question: For how many years did Christopher Jahn work for U.S. Senator Craig Thomas?

Answer: nearly 10 years


Question: What is the full form CSA?

Answer: Contract Services Association


Question: Which number is lightly printed lower-right side of the document?

Answer: 22


Question: what is in the appendix A?

Answer: Mode of Action Analysis for Liver Tumors Based on NCI Slide Reread and RfD Derivation

Question: what is in the appendix A?

Answer: mode of action analysis for liver tumors based on NCI slide reread and Rfd derivation (Dourson et al. 2014)


Question: What is the name of the President of BOARD OF TRUSTEES?

Answer: Michael Leonard Dourson

Question: What is the name of the President of BOARD OF TRUSTEES?

Answer: Michael Leonard Dourson, PhD, DABT, ATS


Question: To which university did William H. Farland belong to?

Answer: Colorado State University


Question: What is the timing mentioned?

Answer: a one week turnaround, depending upon availability

Question: What is the timing mentioned?

Answer: Toxys offers a one week turnaround, depending upon availability


Question: What is the Total Project Cost?

Answer: 56,400


Question: What is the heading of the budget table?

Answer: For 5 Test Articles - Phase IB (definitive)


Question: What is the heading of the document?

Answer: Thank You


Question: Who are the Publication co-authors?

Answer: Michael Dourson, Bernard Gadagbui, John Lowe and Rod Thompson


Question: what is the full form of ppe?

Answer: Personal Protective Equipment

Question: what is the full form of ppe?

Answer: personal protective equipment


Question: what is the subtitle for research foundation?

Answer: Research for the NFPA Mission

Question: what is the subtitle for research foundation?

Answer: research for the NFPA mission


Question: what is the phone number for david bernzweig under the list of "project technical panel"?

Answer: 614-774-7446


Question: what is the email id for bryan ormand under the list of 'project technical panel'?

Answer: rbormond@ncsu.edu


Question: What is the fullform of TCE?

Answer: Trichloroethylene


Question: How many scientists from multiple international organizations are invited?

Answer: over 300 scientists


Question: When was ARA TCE Workgroup formed?

Answer: in the fall of 2012

Question: When was ARA TCE Workgroup formed?

Answer: ARA TCE Workgroup formed in the Fall of 2012


Question: What is the abbreviation of Alliance for Risk Assessment?

Answer: ARA


Question: What does Figure 2 represents?

Answer: Ah Receptor Activation - HIPS with and without FR


Question: What is the page no mentioned in this document?

Answer: 10


Question: What is the handwritten  date  above the signature?

Answer: 3/29/2017

Question: What is the handwritten  date  above the signature?

Answer: 3 / 29 / 2017


Question: Who has signed the document?

Answer: E. Scott Pruitt


Question: What is the designation of E. Scott Pruitt?

Answer: Administrator


Question: What does Figure 1 represents?

Answer: Project Conceptual Approach


Question: What is the fullform of PPE?

Answer: Personal Protective Equipment


Question: What is the last updated date mentioned in this document?

Answer: 5 February 2016


Question: On which date is the senior steering committee meeting conducted?

Answer: Thursday August 17, 2017


Question: At what time is the senior steering committee meeting scheduled ?

Answer: 1:00pm - 3:00pm EST


Question: between what timings the welcome is sheduled ?

Answer: 1:00pm-1:03pm

Question: between what timings the welcome is sheduled ?

Answer: 1:00PM-1:03PM


Question: What is the agenda between 1:03pm-1:05pm?

Answer: Roll Call


Question: What time is the subcommittee updates discussed?

Answer: 1:10PM - 1:20PM


Question: what is the agenda between 1:40 pm-2:00 pm ?

Answer: Summary of Action Items

Question: what is the agenda between 1:40 pm-2:00 pm ?

Answer: summary of action items


Question: what is the passcode number ?

Answer: 202-564-2754


Question: Where is the senior steering committee meeting held?

Answer: HHS Hubert Humphery building -Room 325A


Question: what is the given dail-in number ?

Answer: 1-866-299-3188


Question: What is the fullform of NASDA?

Answer: National Association of State Departments of Agriculture

Question: What is the fullform of NASDA?

Answer: The National Association of State Departments of Agriculture


Question: When did NASDA submitted comments to EPA?

Answer: January 2016


Question: What is the issued date of this document?

Answer: March 29 2017

Question: What is the issued date of this document?

Answer: March 29 , 2017


Question: Who is the Louisiana Commissioner of Agriculture & Forestry?

Answer: Dr. Mike Strain


Question: what is the given location ?

Answer: New York, NY


Question: who reviewed the overall objectives for the meeting ?

Answer: K. White


Question: what are the units of BW ?

Answer: kg


Question: what is the value CSF ?

Answer: 0.1


Question: what is kg mentioned as ?

Answer: kilograms


Question: what is L/d mentioned as ?

Answer: Liters per day

Question: what is L/d mentioned as ?

Answer: liters per day


Question: what is the value of conversion factor ?

Answer: 1,000


Question: what is RSC stands for ?

Answer: Relative Source Contribution

Question: what is RSC stands for ?

Answer: relative source contribution


Question: what is TR stands for ?

Answer: Target Risk

Question: what is TR stands for ?

Answer: target risk


Question: what is the unit of uncertainty factor ?

Answer: Unitless

Question: what is the unit of uncertainty factor ?

Answer: unitless


Question: what is NFSD?

Answer: Nordic Fire & Safety Days

Question: what is NFSD?

Answer: nordic fire & safety days


Question: when does the session end?

Answer: 16:45


Question: what is the P&B score for persistent and bioaccumulative

Answer: 5


Question: what is the p&B ranking for not persistent and not bioaccumulative

Answer: Low

Question: what is the p&B ranking for not persistent and not bioaccumulative

Answer: low


Question: what is the exposure rank for the combined score-All 3 elements 11-13

Answer: High

Question: what is the exposure rank for the combined score-All 3 elements 11-13

Answer: high


Question: which priority groups are deemed as  high priority groups?

Answer: priority groups 7,8, and 9


Question: which priority groups are deemed as medium priority groups?

Answer: priority groups 4,5, and 6


Question: which priority groups are deemed as low priority groups ?

Answer: Priority groups 2 and 3


Question: in which year this data was published ?

Answer: 2011


Question: what is the date mentioned in this invoice?

Answer: June 24, 2016


Question: what is the total amount of the invoice?

Answer: $27,600.00


Question: What is the invoice# given?

Answer: ACCTCESystemJul16


Question: What does FR stand for?

Answer: fire retardant


Question: what is the use of fire retardant plastics?

Answer: Fire Retardant (FR) plastics are used in many products(toys, chairs, electronics, etc.) to reduce the risk of fire and burn hazards.


Question: What happens if enough flammable gas is produced ?

Answer: the battery casing can fail releasing the gas, which can potentially ignited surrounding materials and cause a fire.


Question: Who is mentioned in the CC:?

Answer: OCSPP senior staff Justina Fugh, Senior Counsel for Ethics


Question: who is the CEO of National Association of Wheat Growers?

Answer: Chandler Goule


Question: When did Chandler Goule assume his responsibilities as CEO?

Answer: July 5, 2016

Question: When did Chandler Goule assume his responsibilities as CEO?

Answer: on July 5, 2016.